Verrica Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview

Verrica Pharmaceuticals

02/08/2024 17:16

* Verrica Pharmaceuticals Inc  VRCA.OQ   VRCA.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 6 (estimated) for the period ending June 30 2024
    * The West Chester Pennsylvania-based  company is expected
to
report a 2,299.2% increase in revenue to $4.367 million from
$182 thousand a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Verrica Pharmaceuticals
Inc is
for a loss of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $14.50​, above​ its last closing price
of $6.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.46       -0.40      -0.44     Missed  -10.9
 Dec. 31 2024  -0.53       -0.53      -0.53     Met     -0.4
 Sep. 30 2023  -0.35       -0.36      -0.54     Missed  -49.5​
 Jun. 30 2023  -0.22       -0.21      -0.24     Missed  -14.2
 ​​Jan.        -0.18       -0.19      -0.15     Beat    21.1
 1 0001                                                 
 Dec. 31 2022  -0.19       -0.19      -0.14     Beat    27.3​
 Sep. 30 2022  -0.17       -0.11      0.03      Beat    126.4
 Jun. 30 2022  -0.28       -0.32      -0.37     Missed  -15.3
 This summary was machine generated August 2 at 16:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)